Skip to content
Life Sciences Series A Founded 2012

Apton Biosystems

Apton Biosystems develops a sequencing-based molecular profiling platform with a high-throughput system for human genome sequencing that also analyzes proteins and nucleic acids. The system enables biomarker discovery, early disease detection, and therapeutic monitoring using single-molecule detection technology for individual cancer biomarkers. Founded in 2012 in Pleasanton, United States, the company has raised…

📍 Pleasanton, United States · Genomics,

Funding snapshot

Last roundSeries A
Amount$24M
Date30 June 2021
Total raised$35M
Team size4

About

Apton Biosystems develops a sequencing-based molecular profiling platform with a high-throughput system for human genome sequencing that also analyzes proteins and nucleic acids. The system enables biomarker discovery, early disease detection, and therapeutic monitoring using single-molecule detection technology for individual cancer biomarkers. Founded in 2012 in Pleasanton, United States, the company has raised $34.5M in Series A funding from investors including Khosla Ventures, Samsung Catalyst Fund, and Casdin Capital. Developer of a sequencing-based molecular profiling platform. The platform is developing a high throughput system for the human genome sequence. The system can also analyze several proteins and nucleic acids. Also, it allows biomarker discovery, early disease detection, and therapeutic monitoring.

Business model

Oncology > In-Vitro Diagnostic Tests > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine

Team background

College Wise > University of California (Berkeley), Stanford University

Institutional investors

Khosla Ventures Kern Capital Casdin Capital Samsung Catalyst Fund Cenova Tri-Valley Ventures

Latest coverage

No articles yet.

Raising like Apton Biosystems?

Analyze your pitch deck before your next raise.

Analyze My Deck →